Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis

Regorafenib is an orally administered multikinase inhibitor indicated for the treatment of heavily pretreated metastatic colorectal cancer patients with good performance status, albeit less than 50% treated patients achieve disease stabilisation or better at the first radiological evaluation. In add...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Giampieri, Riccardo, Prete, Michela del, Prochilo, Tiziana, Puzzoni, Marco, Pusceddu, Valeria, Pani, Fabiana, Maccaroni, Elena, Mascia, Roberta, Baleani, Maria Giuditta, Meletani, Tania, Berardi, Rossana, Lanzillo, Anna Maria, Mariotti, Stefano, Zaniboni, Alberto, Cascinu, Stefano, Scartozzi, Mario
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380985/
https://ncbi.nlm.nih.gov/pubmed/28378839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep45703
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky